nodes	percent_of_prediction	percent_of_DWPC	metapath
Acebutolol—Atrioventricular block second degree—Hydrochlorothiazide—nephrolithiasis	0.0665	0.0867	CcSEcCtD
Acebutolol—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.0544	0.0709	CcSEcCtD
Acebutolol—SLC22A1—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0314	0.135	CbGpPWpGaD
Acebutolol—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0299	0.039	CcSEcCtD
Acebutolol—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.0276	0.036	CcSEcCtD
Acebutolol—ADRB1—Endothelin Pathways—ADCY10—nephrolithiasis	0.0242	0.104	CbGpPWpGaD
Acebutolol—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0205	0.0267	CcSEcCtD
Acebutolol—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0185	0.0241	CcSEcCtD
Acebutolol—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0147	0.0192	CcSEcCtD
Acebutolol—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0191	CcSEcCtD
Acebutolol—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0191	CcSEcCtD
Acebutolol—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.0146	0.019	CcSEcCtD
Acebutolol—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.0138	0.018	CcSEcCtD
Acebutolol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0136	0.0177	CcSEcCtD
Acebutolol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0131	0.017	CcSEcCtD
Acebutolol—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.0126	0.0164	CcSEcCtD
Acebutolol—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0124	0.0162	CcSEcCtD
Acebutolol—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0145	CcSEcCtD
Acebutolol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.011	0.0143	CcSEcCtD
Acebutolol—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0141	CcSEcCtD
Acebutolol—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0139	CcSEcCtD
Acebutolol—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0103	0.0135	CcSEcCtD
Acebutolol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0133	CcSEcCtD
Acebutolol—ADRB1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0101	0.0432	CbGpPWpGaD
Acebutolol—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00992	0.0129	CcSEcCtD
Acebutolol—ADRB2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00984	0.0422	CbGpPWpGaD
Acebutolol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00972	0.0127	CcSEcCtD
Acebutolol—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00957	0.0125	CcSEcCtD
Acebutolol—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0095	0.0124	CcSEcCtD
Acebutolol—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00947	0.0123	CcSEcCtD
Acebutolol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0092	0.012	CcSEcCtD
Acebutolol—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.0089	0.0116	CcSEcCtD
Acebutolol—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00886	0.0115	CcSEcCtD
Acebutolol—ADRB1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00846	0.0363	CbGpPWpGaD
Acebutolol—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00843	0.011	CcSEcCtD
Acebutolol—ADRB2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00828	0.0355	CbGpPWpGaD
Acebutolol—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00819	0.0107	CcSEcCtD
Acebutolol—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00804	0.0105	CcSEcCtD
Acebutolol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00783	0.0102	CcSEcCtD
Acebutolol—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00771	0.0101	CcSEcCtD
Acebutolol—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00749	0.00977	CcSEcCtD
Acebutolol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00746	0.00973	CcSEcCtD
Acebutolol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00745	0.00971	CcSEcCtD
Acebutolol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00734	0.00957	CcSEcCtD
Acebutolol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.0073	0.00952	CcSEcCtD
Acebutolol—Cough—Hydrochlorothiazide—nephrolithiasis	0.00725	0.00945	CcSEcCtD
Acebutolol—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00707	0.00922	CcSEcCtD
Acebutolol—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00707	0.00922	CcSEcCtD
Acebutolol—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00707	0.00922	CcSEcCtD
Acebutolol—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00705	0.00919	CcSEcCtD
Acebutolol—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00699	0.00911	CcSEcCtD
Acebutolol—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00684	0.00891	CcSEcCtD
Acebutolol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00678	0.00884	CcSEcCtD
Acebutolol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00667	0.0087	CcSEcCtD
Acebutolol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00655	0.00855	CcSEcCtD
Acebutolol—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00646	0.00843	CcSEcCtD
Acebutolol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00634	0.00826	CcSEcCtD
Acebutolol—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00629	0.027	CbGpPWpGaD
Acebutolol—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00805	CcSEcCtD
Acebutolol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00617	0.0265	CbGpPWpGaD
Acebutolol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00613	0.008	CcSEcCtD
Acebutolol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00609	0.00794	CcSEcCtD
Acebutolol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00604	0.00788	CcSEcCtD
Acebutolol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00604	0.0259	CbGpPWpGaD
Acebutolol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00603	0.00786	CcSEcCtD
Acebutolol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00597	0.00778	CcSEcCtD
Acebutolol—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00589	0.00768	CcSEcCtD
Acebutolol—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00585	0.0251	CbGpPWpGaD
Acebutolol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00585	0.00762	CcSEcCtD
Acebutolol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0058	0.00756	CcSEcCtD
Acebutolol—Pain—Hydrochlorothiazide—nephrolithiasis	0.0058	0.00756	CcSEcCtD
Acebutolol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00559	0.00728	CcSEcCtD
Acebutolol—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00554	0.00723	CcSEcCtD
Acebutolol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00539	0.00702	CcSEcCtD
Acebutolol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00699	CcSEcCtD
Acebutolol—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00699	CcSEcCtD
Acebutolol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00486	0.00634	CcSEcCtD
Acebutolol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.0048	0.00625	CcSEcCtD
Acebutolol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00464	0.00605	CcSEcCtD
Acebutolol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00448	0.00585	CcSEcCtD
Acebutolol—ADRB2—GPCRs, Other—CHRM3—nephrolithiasis	0.00437	0.0188	CbGpPWpGaD
Acebutolol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00562	CcSEcCtD
Acebutolol—Rash—Hydrochlorothiazide—nephrolithiasis	0.00428	0.00557	CcSEcCtD
Acebutolol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00427	0.00557	CcSEcCtD
Acebutolol—Headache—Hydrochlorothiazide—nephrolithiasis	0.00425	0.00554	CcSEcCtD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00412	0.0177	CbGpPWpGaD
Acebutolol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00403	0.00525	CcSEcCtD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00377	0.0162	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00377	0.0162	CbGpPWpGaD
Acebutolol—ADRB1—G alpha (s) signalling events—PTH—nephrolithiasis	0.00319	0.0137	CbGpPWpGaD
Acebutolol—ADRB2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00312	0.0134	CbGpPWpGaD
Acebutolol—ADRB1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00301	0.0129	CbGpPWpGaD
Acebutolol—ADRB2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00295	0.0126	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00286	0.0123	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00286	0.0123	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00266	0.0114	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00266	0.0114	CbGpPWpGaD
Acebutolol—SLC22A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00237	0.0102	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00235	0.0101	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00235	0.0101	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.0021	0.00899	CbGpPWpGaD
Acebutolol—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00204	0.00876	CbGpPWpGaD
Acebutolol—ADRB1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00194	0.00833	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00192	0.00822	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00192	0.00822	CbGpPWpGaD
Acebutolol—ADRB2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0019	0.00815	CbGpPWpGaD
Acebutolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00166	0.00714	CbGpPWpGaD
Acebutolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00163	0.00699	CbGpPWpGaD
Acebutolol—ADRB1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00147	0.00629	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00145	0.00623	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00145	0.00623	CbGpPWpGaD
Acebutolol—ADRB2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00143	0.00616	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00138	0.00591	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00138	0.00591	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00135	0.00579	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00135	0.00579	CbGpPWpGaD
Acebutolol—ADRB1—Signaling by GPCR—RGS14—nephrolithiasis	0.00133	0.00571	CbGpPWpGaD
Acebutolol—ADRB2—Signaling by GPCR—RGS14—nephrolithiasis	0.0013	0.00559	CbGpPWpGaD
Acebutolol—ADRB1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00127	0.00544	CbGpPWpGaD
Acebutolol—ADRB2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00124	0.00532	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00123	0.00527	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0012	0.00516	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0012	0.00516	CbGpPWpGaD
Acebutolol—ADRB1—GPCR ligand binding—PTH—nephrolithiasis	0.00116	0.00497	CbGpPWpGaD
Acebutolol—ADRB2—GPCR ligand binding—PTH—nephrolithiasis	0.00113	0.00487	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00112	0.00482	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00112	0.00482	CbGpPWpGaD
Acebutolol—ADRB1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00099	0.00425	CbGpPWpGaD
Acebutolol—ADRB2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000969	0.00416	CbGpPWpGaD
Acebutolol—SLC22A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000962	0.00413	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—ADCY10—nephrolithiasis	0.000925	0.00397	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—ADCY10—nephrolithiasis	0.000905	0.00388	CbGpPWpGaD
Acebutolol—ADRB1—Signaling by GPCR—DGKH—nephrolithiasis	0.000899	0.00386	CbGpPWpGaD
Acebutolol—ADRB2—Signaling by GPCR—DGKH—nephrolithiasis	0.00088	0.00378	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000851	0.00365	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000851	0.00365	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—GRHPR—nephrolithiasis	0.000834	0.00358	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000791	0.0034	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000791	0.0034	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—RGS14—nephrolithiasis	0.000787	0.00338	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—RGS14—nephrolithiasis	0.000769	0.0033	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—AGXT—nephrolithiasis	0.000744	0.00319	CbGpPWpGaD
Acebutolol—ADRB1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000716	0.00307	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000705	0.00303	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000705	0.00303	CbGpPWpGaD
Acebutolol—ADRB2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0007	0.00301	CbGpPWpGaD
Acebutolol—ADRB1—GPCR downstream signaling—PTH—nephrolithiasis	0.000655	0.00281	CbGpPWpGaD
Acebutolol—ADRB1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00065	0.00279	CbGpPWpGaD
Acebutolol—ADRB2—GPCR downstream signaling—PTH—nephrolithiasis	0.000641	0.00275	CbGpPWpGaD
Acebutolol—ADRB2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000636	0.00273	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—SLC26A1—nephrolithiasis	0.000632	0.00271	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—APRT—nephrolithiasis	0.000632	0.00271	CbGpPWpGaD
Acebutolol—ADRB1—Signaling by GPCR—PTH—nephrolithiasis	0.000595	0.00255	CbGpPWpGaD
Acebutolol—ADRB2—Signaling by GPCR—PTH—nephrolithiasis	0.000582	0.0025	CbGpPWpGaD
Acebutolol—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000564	0.00242	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000531	0.00228	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—DGKH—nephrolithiasis	0.000531	0.00228	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00052	0.00223	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—DGKH—nephrolithiasis	0.00052	0.00223	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000489	0.0021	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000461	0.00198	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—AQP1—nephrolithiasis	0.000451	0.00193	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000436	0.00187	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000411	0.00176	CbGpPWpGaD
Acebutolol—SLC22A1—Metabolism—CHRM3—nephrolithiasis	0.000407	0.00175	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—CHRM3—nephrolithiasis	0.000384	0.00165	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—CHRM3—nephrolithiasis	0.000376	0.00161	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—APRT—nephrolithiasis	0.000371	0.00159	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000371	0.00159	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—PTH—nephrolithiasis	0.000351	0.00151	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000349	0.0015	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000349	0.0015	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—PTH—nephrolithiasis	0.000344	0.00147	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000264	0.00113	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000249	0.00107	CbGpPWpGaD
Acebutolol—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000239	0.00102	CbGpPWpGaD
Acebutolol—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000225	0.000966	CbGpPWpGaD
Acebutolol—ADRB1—Signaling Pathways—SPP1—nephrolithiasis	0.000176	0.000757	CbGpPWpGaD
Acebutolol—ADRB2—Signaling Pathways—SPP1—nephrolithiasis	0.000173	0.00074	CbGpPWpGaD
